PMID- 35255440
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220809
IS  - 2468-2942 (Electronic)
IS  - 2468-2942 (Linking)
VI  - 31
DP  - 2022
TI  - New diagnostic measures of oxaliplatin-induced peripheral sensory neuropathy.
PG  - 100543
LID - S2468-2942(22)00034-X [pii]
LID - 10.1016/j.ctarc.2022.100543 [doi]
AB  - OBJECTIVE: Oxaliplatin-induced peripheral neuropathy (OIPN) is an unwanted side 
      effect of oxaliplatin chemotherapy treatment. OIPN manifests in an acute phase 
      that lasts a few days after injection and a persistent phase that may become 
      chronic. Currently, there is no consensus about a clinically applicable, 
      quantitative, and objective measure of OIPN. METHODS: Seventeen patients treated 
      with oxaliplatin containing adjuvant chemotherapy for stage III colon cancer, but 
      otherwise healthy, were tested with six quantitative sensory tests (QST) and five 
      large fibre perception threshold tracking (PTT) measures (quantified by, e.g., 
      rheobase and electrotonus threshold) one hour before each of the 12 chemotherapy 
      cycles given at two weeks' intervals. These measures were repeated at 3, 6, and 
      12-month follow-ups. The temporal development of OIPN assessed by the Common 
      Terminology Criteria for Adverse Events (CTCAE) scale, QST, and PTT measures was 
      calculated by linear regression. RESULTS: The CTCAE score showed a tri-phasic 
      increase during the treatment and remained increased during the follow-up. The 
      vibration threshold (R = 0.25, p<0.001), the cold pain threshold (R = 0.17, 
      p = 0.02), and the rheobase (R = 0.28, p < 0.001) increased during treatment, 
      whereas the cold detection threshold (R=-0.16, p = 0.002) decreased. The cold 
      pain threshold and the rheobase remained increased, and the cold detection and 
      heat pain threshold remained decreased during follow-up. CONCLUSIONS: Increased 
      cold pain sensitivity and decreased large fibre sensitivity (increased rheobase) 
      correlate to the persistent OIPN, whereas the CTCAE score assesses both acute and 
      persistent OIPN. Furthermore, the novel PTT method assessed the nerve 
      excitability changes caused by the oxaliplatin.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Szpejewska, Joanna E
AU  - Szpejewska JE
AD  - Department of Oncology, Clinical Cancer Research Centre, Aalborg University 
      Hospital, Hobrovej 18-22, Aalborg, 9000 Denmark; Department of Oncology and 
      Palliative Care, Zealand University Hospital Roskilde, Vestermarksvej 9, 
      Roskilde, 4000 Denmark.
FAU - Yilmaz, Mette
AU  - Yilmaz M
AD  - Department of Oncology, Clinical Cancer Research Centre, Aalborg University 
      Hospital, Hobrovej 18-22, Aalborg, 9000 Denmark.
FAU - Falkmer, Ursula G
AU  - Falkmer UG
AD  - Department of Oncology, Clinical Cancer Research Centre, Aalborg University 
      Hospital, Hobrovej 18-22, Aalborg, 9000 Denmark; Department of Clinical Medicine, 
      Aalborg University, Hobrovej 18-22, Aalborg, 9000 Denmark.
FAU - Arendt-Nielsen, Lars
AU  - Arendt-Nielsen L
AD  - Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and 
      Technology, School of Medicine, Aalborg University, Frederik Bajers Vej 7, 
      Aalborg, 9220 Denmark; Department of Medical Gastroenterology, Mech-Sense, 
      Aalborg University Hospital, Aalborg, 9000 Denmark.
FAU - Morch, Carsten D
AU  - Morch CD
AD  - Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and 
      Technology, School of Medicine, Aalborg University, Frederik Bajers Vej 7, 
      Aalborg, 9220 Denmark. Electronic address: cdahl@hst.aau.dk.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220302
PL  - England
TA  - Cancer Treat Res Commun
JT  - Cancer treatment and research communications
JID - 101694651
RN  - 0 (Antineoplastic Agents)
RN  - 04ZR38536J (Oxaliplatin)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - *Colonic Neoplasms
MH  - Humans
MH  - Oxaliplatin/adverse effects
MH  - Pain/drug therapy
MH  - *Peripheral Nervous System Diseases/chemically induced/diagnosis
EDAT- 2022/03/08 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/03/07 20:13
PHST- 2021/12/27 00:00 [received]
PHST- 2022/02/22 00:00 [revised]
PHST- 2022/02/27 00:00 [accepted]
PHST- 2022/03/08 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/03/07 20:13 [entrez]
AID - S2468-2942(22)00034-X [pii]
AID - 10.1016/j.ctarc.2022.100543 [doi]
PST - ppublish
SO  - Cancer Treat Res Commun. 2022;31:100543. doi: 10.1016/j.ctarc.2022.100543. Epub 
      2022 Mar 2.